Lonza Biologics Inc.

CROPseq-iT7 backbone and Brunello library were cloned, tissue culture conditions for various cell lines were established, and library transduction and quality control were performed. NIS-Seq perturbation screens were conducted, and imaging and image analysis were detailed. Single-gene perturbation cell lines were generated for validation, and primary human macrophages were differentiated, transduced, and nucleofected. Inflammasome stimulation and human epidermal sheet preparation, transduction, and sequencing were also described. Zero-knowledge image analysis using deep learning was performed, and ethics statements were included.

Celltrion Inc. launches Celltrion BioSolutions Co., entering the CDMO market with plans to build a 800 billion won plant in Korea, targeting 3 trillion won in sales by 2031. The unit aims to differentiate with a variety of drug modalities and CGT services.

Padlock investors sue Bristol Myers Squibb for milestone payment refusal; Gilead appoints Dietmar Berger as top doctor; Boundless Bio execs resign, company halts drug development; Lonza to focus on core CDMO business; Bausch + Lomb explores potential sale.

Elevation Oncology, Inc. signs US$368m deal with Synaffix for EO-1022 ADC development, excluding Lonza's ADC manufacturing services. Synaffix provides global access to its ADC technology platform, eligible for milestone payments and royalties. Elevation Oncology handles ADC research, development, and commercialization. ADCs show higher preclinical-to-clinical transition rates but face toxicity issues, prompting Synaffix to optimize drug-antibody ratios.

Polyethylene glycol (PEG) is crucial in medical applications, enhancing drug bioavailability and reducing immunogenicity. However, PEGylated nanopharmaceuticals have caused side effects, particularly after intravenous administration. PEG's mechanism of side effects is unclear but may involve immune response stimulation. Studies show PEG can induce cytokine production and neutrophil extracellular trap formation, potentially through Ca²⁺ signaling, highlighting the need for further research on PEG's immunological effects.

FMI forecasts the global automated cell biology systems market to reach USD 33.5 billion by 2032, driven by tech advancements and lab automation, with a CAGR of 9.0%. This growth signifies a transformative shift in biotech, enhancing research efficiency and paving the way for scientific innovation. Key drivers include rising demand for personalized medicine, increased investments in cell biology research, and technological advancements.

The Microplate Reader Market was valued at USD 486.89 million in 2023 and is projected to grow to USD 941.32 million by 2032, expanding at a CAGR of 7.6%. This growth is driven by increasing demand for precise and high-throughput analysis in drug discovery, genomics, and diagnostic applications, especially in the pharmaceutical, biotechnology, and research sectors.

AI in pharma addresses R&D costs, supply chain complexity, and data management by accelerating drug development, automating compliance, managing large datasets, and optimizing clinical trials. Swiss startup Risklick uses AI to streamline clinical trial protocols and integrate historical data. As AI evolves, stakeholders must integrate these innovations to optimize research, enhance data-driven decisions, and meet patient needs.

The microbial fermentation technology market was valued at USD 31.97 Billion in 2023 and is projected to reach USD 53.25 Billion by 2032, growing at a CAGR of 5.91%. This growth is driven by advancements in biotechnology, demand for sustainable production, and investments in alternative protein companies. Key segments include antibiotics, monoclonal antibodies, and CMOs & CDMOs, with Asia Pacific leading the market and North America poised for fast growth.

Lonza expands services to support smart capsule companies developing oral biologics, offering bespoke development and manufacturing tailored to specific needs. The market for oral biologics is expected to grow at a 35% CAGR from 2023–2028. Lonza also adds bioconjugation capacity at its Visp site, doubling production for bioconjugates by 2028.